quantisnow
FeedTopReportsPricing
⌘K
Live feed
02:00:00·185d
PRRelease
GSK plc logo
Spero Therapeutics Inc. logo

PIVOT-PO Phase 3 Data Show Tebipenem HBr's Potential as the First Oral Carbapenem Antibiotic for Patients with Complicated Urinary Tract Infections (cUTIs)

GSK· GSK plcSPRO· Spero Therapeutics Inc.
Health Care
Original source

Companies

  • GSK
    GSK plc
    Health Care
  • SPRO
    Spero Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Jan 27GSKUpdateCitigroup-
  • Jan 6GSKUpdateBarclays-
  • Nov 25GSKUpdateBofA Securities-
  • Jun 3GSKUpdateBerenberg-
  • Apr 15GSKUpdateExane BNP Paribas$35.25
  • Feb 12GSKUpdateMorgan Stanley-

Related

  • SEC1d
    SEC Form 6-K filed by GSK plc
  • SEC2d
    SEC Form 6-K filed by GSK plc
  • SEC3d
    SEC Form 6-K filed by GSK plc
  • SEC3d
    SEC Form 6-K filed by GSK plc
  • SEC4d
    SEC Form 6-K filed by GSK plc
  • SEC4d
    SEC Form 6-K filed by GSK plc
  • SEC7d
    SEC Form 6-K filed by GSK plc
  • SEC7d
    SEC Form 6-K filed by GSK plc
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022